Advanced search
Publication Cover
Drug Design, Development and Therapy Volume 18, 2024 - Issue
Submit an article Journal homepage
50
Views
0
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Outcome of Darunavir–Cobicistat-Based Regimens in HIV-Infected People Who Have Experienced Virological Failure

Francesca Alberton1 Infectious Diseases Unit, Vita Salute San Raffaele University, Milan, ItalyView further author information
,
Laura Galli2 Infectious Diseases Unit, San Raffaele Scientific Institute, Milan, ItalyORCID Iconhttps://orcid.org/0000-0001-8046-0290View further author information
ORCID Icon,
Riccardo Lolatto2 Infectious Diseases Unit, San Raffaele Scientific Institute, Milan, ItalyView further author information
,
Caterina Candela1 Infectious Diseases Unit, Vita Salute San Raffaele University, Milan, ItalyView further author information
,
Nicola Gianotti2 Infectious Diseases Unit, San Raffaele Scientific Institute, Milan, ItalyORCID Iconhttps://orcid.org/0000-0002-7182-5080View further author information
ORCID Icon,
Matteo Chiurlo2 Infectious Diseases Unit, San Raffaele Scientific Institute, Milan, ItalyORCID Iconhttps://orcid.org/0009-0001-9480-7037View further author information
ORCID Icon,
Martina Ranzenigo2 Infectious Diseases Unit, San Raffaele Scientific Institute, Milan, ItalyView further author information
,
Martina Strano2 Infectious Diseases Unit, San Raffaele Scientific Institute, Milan, ItalyView further author information
,
Alessia Uglietti3 Medical Affairs Department, Infectious Diseases and Vaccines & Rare Diseases, Johnson&Johnson, Milan, ItalyCorrespondence[email protected]
View further author information
&
Antonella Castagna1 Infectious Diseases Unit, Vita Salute San Raffaele University, Milan, Italy;2 Infectious Diseases Unit, San Raffaele Scientific Institute, Milan, ItalyView further author information
 show all
Pages 1153-1163 | Received 09 Oct 2023, Accepted 09 Mar 2024, Published online: 09 Apr 2024

References

  • EACS Guidelines version 11.1; 2022. Available from: https://eacs.sanfordguide.com/. Accessed July 14, 2023.
  • Clotet B, Bellos N, Molina J-M, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet. 2007;369(9568):1169–1178. doi:10.1016/S0140-6736(07)60497-8
  • Katlama C, Haubrich R, Lalezari J, et al. Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials. AIDS. 2009;23(17):2289–2300. doi:10.1097/QAD.0b013e3283316a5e
  • Cahn P, Fourie J, Grinsztejn B, et al. Week 48 analysis of once-daily vs. twice-daily darunavir/ritonavir in treatment experienced HIV-1-infected patients. AIDS. 2011;25(7):929–939. doi:10.1097/QAD.0b013e328345ee95
  • Orkin C, Eron JJ, Rockstroh J, et al. Week 96 results of a Phase 3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients. AIDS. 2020;34(5):707–718. doi:10.1097/QAD.0000000000002463
  • Tashima K, Crofoot G, Tomaka FL, et al. Cobicistat-boosted darunavir in HIV-1-infected adults: week 48 results of a Phase IIIb, open-label single-arm trial. AIDS Res Ther. 2014;11(1):39. doi:10.1186/1742-6405-11-39
  • Lee SA, Kim S-W, Chang H-H, et al. Effectiveness, safety, and tolerability of a switch to dual therapy with dolutegravir plus cobicistat-boosted darunavir in treatment-experienced patients with human immunodeficiency virus. Infect Chemother. 2018;50(3):252–262. doi:10.3947/ic.2018.50.3.252
  • Paton NI, Musaazi J, Kityo C, et al. Dolutegravir or darunavir in combination with zidovudine or tenofovir to treat HIV. N Engl J Med. 2021;385(4):330–341. PMID: 34289276. doi:10.1056/NEJMoa2101609
  • Eron JJ, Orkin C, Gallant J, et al. A week-48 randomized phase-3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients. AIDS. 2018;32(11):1431–1442. doi:10.1097/QAD.0000000000001817
  • Huhn GD, Crofoot G, Ramgopal M, et al. Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in a rapid-initiation model of care for human immunodeficiency virus type 1 infection: primary analysis of the diamond study. Clin Infect Dis. 2020;71(12):3110–3117. doi:10.1093/cid/ciz1213
  • Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services; 2023. Available from: https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv. Accessed July 14, 2023.
  • Xu L, Liu H, Murray BP, et al. Cobicistat (GS-9350): a potent and selective inhibitor of human CYP 3A as a novel pharmacoenhancer. ACS Med Chem Lett. 2010;1(5):209–213. doi:10.1021/ml1000257
  • Gallant JE, Koenig E, Andrade-Villanueva J, et al. Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results. J Infect Dis. 2013;208(1):32–39. doi:10.1093/infdis/jit122
  • Bangalore S, Kamalakkannan G, Parkar S, et al. Fixed dose combinations improve medication compliance: a meta-analysis. Am J Med. 2007;120(8):713–719. doi:10.1016/j.amjmed.2006.08.033
  • Gori A, Antinori A, Vergori A, et al. Effectiveness of switching to darunavir/cobicistat in virologically suppressed HIV-positive patients receiving ritonavir-boosted protease inhibitor-based regimen: the ”STORE” Study. Study J Acquir Immune Defic Syndr. 2020;84(3):290–294. PMID: 32101882; PMCID: PMC7289135. doi:10.1097/QAI.0000000000002331
  • Echeverría P, Bonjoch A, Puig J, et al. Significant improvement in triglyceride levels after switching from ritonavir to cobicistat in suppressed HIV-1-infected subjects with dyslipidaemia. HIV Med. 2017;18(10):782–786. PMID: 28671337. doi:10.1111/hiv.12530
  • Taiwo B, Zheng L, Gallien S, et al.; ACTG A5262 Team. Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262). AIDS. 2011;25(17):2113–2122. PMID: 21857490; PMCID: PMC3515052. doi:10.1097/QAD.0b013e32834bbaa9
  • German P, Liu HC, Szwarcberg J, et al. Effect of cobicistat on glomerular filtration rate in subjects with normal and impaired renal function. J Acquir Immune Defic Syndr. 2012;61(1):32–40. doi:10.1097/QAI.0b013e3182645648
  • Abdullahi A, Diaz AG, Fopoussi OM, et al. A detailed characterization of drug resistance during darunavir/ritonavir monotherapy highlights a high barrier to the emergence of resistance mutations in protease but identifies alternative pathways of resistance. J Antimicrob Chemother. 2024;79(2):339–348. doi:10.1093/jac/dkad386

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.